Q1 2024 Earnings Summary
- Increasing Utilization of Surgical Glaucoma Products: Sight Sciences is experiencing strong growth in utilization of its Surgical Glaucoma technologies, with increased usage per surgeon and within facilities, indicating strong underlying demand. This trend is expected to continue, driving revenue growth in upcoming quarters.
- Robust Pipeline of Innovative Products: The company is advancing its pipeline with products such as the intracanalicular scaffold, the Helix stent, currently in animal studies, and sustained release treatments. These innovations demonstrate Sight Sciences' ability to innovate and could contribute to future growth.
- Positive Momentum in TearCare Reimbursement: Early discussions with payers and positive traction with TearCare reimbursement claims suggest potential for favorable reimbursement levels. This could enhance physician economics and drive adoption of TearCare in the Dry Eye segment, leading to accelerated growth in 2025.
- Despite positive performance in Q1, management did not raise full-year guidance, indicating potential risks or uncertainties about future growth. They emphasized the need to see consistent traction and set achievable targets, which may signal caution about meeting or exceeding expectations.
- The account additions in Q1 were lighter than expected, with the company focusing on increasing utilization in existing accounts rather than adding new ones. This reliance on reengaging lost customers might suggest challenges in expanding their customer base. ,
- Uncertainties remain regarding reimbursement coverage for the TearCare system, with the company stating it's still early in the claims process and premature to provide details. Additionally, they acknowledge the need for marketing and education efforts to drive adoption, which could impact profitability.
-
Guidance Decision
Q: Why not raise guidance given strong trends?
A: Management prefers to set achievable targets based on current business observations. While pleased with success, especially in the Surgical Glaucoma segment, they seek consistent traction in regaining momentum, improving utilization, and adding new accounts before adjusting guidance. They will continue to evaluate as the year progresses. -
TearCare Reimbursement
Q: How are TearCare claims progressing? Need heavy marketing?
A: It's early in the claims process for TearCare, but management is optimistic about favorable reimbursement levels for providers and payers. They see an opportunity for education and outreach rather than heavy marketing spend, focusing on creating a new category for procedural intervention in ocular surface disease due to meibomian gland disease. -
Patent Litigation Impact
Q: Can you capture share from Hydrus due to patent case?
A: Management cannot comment on ongoing patent litigation or strategy. They are pleased with the jury verdict on damages and royalties, but future remedies are pending in the court process. -
MIGS Competition Outlook
Q: How is MIGS competition factored into guidance?
A: The MIGS market is healthy and growing, with innovation bringing attention to stand-alone procedures and expanding the interventional mindset. Competitive dynamics are considered favorable for OMNI's success in the short, medium, and long term. Guidance is set prudently, considering LCD uncertainty. -
Pipeline Milestones
Q: Any pipeline milestones in Surgical Glaucoma soon?
A: Management is excited about their pipeline, including the Helix stent in animal studies and work on sustained release technology. They hope to hit milestones later this year to share more details, demonstrating their ability to innovate and commercialize effectively. -
Utilization Trends
Q: How widespread are utilization recovery trends?
A: Utilization trends are broadly positive across the organization, with increased use per surgeon and more surgeons within facilities. There's a large opportunity for growth, having trained about 50% of MIGS surgeons on OMNI. They plan to invest in the sales force to sustain double-digit growth. -
Account Additions
Q: Explain lighter Q1 account adds and outlook.
A: The focus in Q1 was on increasing utilization in existing accounts, as planned. Management expects active accounts to increase throughout 2024, contributing to growth alongside re-engagement with lost customers and training new ones, aiming to return to double-digit growth. -
Re-engaging Accounts
Q: How are you re-engaging lost accounts post-LCD withdrawal?
A: Engagements with previously lost accounts are positive, with no material limitations. The sales force is building capacity and the company is investing in the sales organization to increase utilization, add new accounts, and train new surgeons, supporting growth.